

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Betenbaugh, et al.

Serial No.: 09/930,440

Group Art Unit: to be assigned

Filed: August 16, 2001

Examiner: to be assigned

Title: Engineering Intracellular
Sialylation Pathways

Attorney Docket No.: PF509P2

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

#3

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-GF listed on the attached revised Form PTO/SB/08. Copies of references AA-GF have been provided in U.S. Application Serial No. 09/516,793 (filed on March 1, 2000) to which the present application claims priority under 35 U.S.C. § 120.

References FN-FO were cited in an International Preliminary Examination Report (FP), and reference AE was cited in an International Search Report (FQ), issued in a foreign counterpart of the instant application.

References FR-FX were cited in an International Search Report (FY) issued in a related foreign application.

Moreover, Genbank Accession references AG-FM have been previously reported in an Information Disclosure Statement in a related U.S. patent application encompassing compositions utilized in the present application.

Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.


Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any

of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 08-3425.

Respectfully submitted

Date: DECEMBER 4, 2001



Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

Enclosures